Patents by Inventor Hans-Peter Vornlocher

Hans-Peter Vornlocher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240191240
    Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multigene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or t9o produce new or altered phenotypes in cells or organisms.
    Type: Application
    Filed: September 13, 2023
    Publication date: June 13, 2024
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K.H. Neuman
  • Publication number: 20240150757
    Abstract: Provided herein are compositions and methods for treating and/or ameliorating FOXG1 syndrome or the symptoms associated therewith. The compositions and methods disclosed herein utilize antisense oligonucleotides that target FOXG1 in order to modulate FOXG1 by, for example, increasing the amount of FOXG1 (e.g. mRNA encoding a FOXG1 protein or FOXG1 protein) in a cell, thereby restoring FOXG1 function.
    Type: Application
    Filed: June 16, 2023
    Publication date: May 9, 2024
    Inventors: Scott REICH, Hans-Peter VORNLOCHER, Anke GEICK, Brian BETTENCOURT
  • Publication number: 20240093192
    Abstract: Provided herein are compositions and methods for treating and/or ameliorating the FOXG1 syndromes or the symptoms associated therewith. The compositions and methods disclosed herein utilize antisense oligonucleotides that target long non-coding RNAs (lncRNAs) to increase FOXG1 expression in a cell, thereby restoring FOXG1 function.
    Type: Application
    Filed: June 16, 2023
    Publication date: March 21, 2024
    Inventors: Scott REICH, Hans-Peter Vornlocher, Anke Geick, Brian Bettencourt
  • Patent number: 11767531
    Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.
    Type: Grant
    Filed: May 18, 2022
    Date of Patent: September 26, 2023
    Assignee: MPEG LA, LLC
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K. H. Neuman
  • Publication number: 20230287406
    Abstract: The present disclosure relates to multimeric oligonucleotides having monomeric subunits joined by linkers and methods of administering multimeric oligonucleotides to a subject. The multimeric oligonucleotides have a molecular weight and/or size configured to increase in vivo activity of one or more subunits within the multimeric oligonucleotide relative to in vivo activity of the same subunit when administered in monomeric form. The present disclosure also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Application
    Filed: March 3, 2020
    Publication date: September 14, 2023
    Inventors: Jonathan Miles Brown, Kristin K.H. Neuman, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20220290148
    Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or t9o produce new or altered phenotypes in cells or organisms.
    Type: Application
    Filed: May 18, 2022
    Publication date: September 15, 2022
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K.H. Neuman
  • Publication number: 20220235361
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 28, 2022
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 11352629
    Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 7, 2022
    Assignee: MPEG LA, L.L.C.
    Inventors: Philipp Hadwiger, Hans-Peter Vornlocher, Jonathan Miles Brown, James Everett Dahlman, Kristin K. H. Neuman
  • Publication number: 20220112505
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 11208662
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: December 28, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Publication number: 20210380979
    Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Application
    Filed: July 1, 2021
    Publication date: December 9, 2021
    Inventors: Jonathan Miles Brown, Kristin K.H. Neuman, Hans-Peter Vornlocher, Philipp Hadwiger
  • Patent number: 11078484
    Abstract: The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: August 3, 2021
    Assignee: MPEG LA, LLC
    Inventors: Jonathan Miles Brown, Kristin K. H. Neuman, Hans-Peter Vornlocher, Philipp Hadwiger
  • Publication number: 20210189393
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: February 23, 2021
    Publication date: June 24, 2021
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20210187007
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: June 24, 2021
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Saetrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Patent number: 10912790
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: February 9, 2021
    Assignee: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200376020
    Abstract: The invention relates to saRNA targeting a C/EBP? transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
    Type: Application
    Filed: April 21, 2016
    Publication date: December 3, 2020
    Applicant: MiNA THERAPEUTICS LIMITED
    Inventors: Andreas Wagner, Robert Habib, Hans E. Huber, Pål Sætrom, Endre Bakken Stovner, Markus Hossbach, Monika Krampert, Hans-Peter Vornlocher
  • Publication number: 20200231968
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Application
    Filed: November 4, 2019
    Publication date: July 23, 2020
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Publication number: 20200157550
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, JR., Hans-Peter Vornlocher
  • Patent number: 10544418
    Abstract: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 28, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gino Van Heeke, Emma Hickman, Henry Luke Danahay, Pamela Tan, Anke Geick, Hans-Peter Vornlocher
  • Patent number: 10501740
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: December 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore